Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.75 |
| ▸ | PTPRF | P10586 | 1/20 | 0.75 |
| ▸ | PTPRA | P18433 | 1/20 | 0.75 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.75 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.75 |
| ▸ | PPARG | P37231 | 8/20 | 0.63 |
| ▸ | PPARA | Q07869 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261645 | 0.86 | PTPN1 (1.00) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL7498026 | 0.86 | PTPN1 (1.00) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL7502934 | 0.86 | PTPN1 (1.00) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL7503246 | 0.84 | PTPN1 (1.00) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL7497871 | 0.83 | PTPN1 (1.00) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL7500549 | 0.81 | PTPN1 (1.00) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| Tromethamine SCHEMBL7501623 | 0.79 | PTPN1 (0.85) | PTPN1PTPRFPTPRAPTPN7DUSP3 | |
| SCHEMBL20553481 | 0.79 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL20553479 | 0.79 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL7496389 | 0.77 | PPARG (0.66) | PTPN1PTPRFPTPRAPTPN7DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077967-B1 | BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | WYETH CORP (US) | 2002-12-04 | — | — | EP | claimed |
| US-20010053785-A1 | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2001-12-20 | — | — | US | claimed |
| US-20010041715-A1 | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PRODUCTS | 2001-11-15 | — | — | US | claimed |
| US-6232322-B1 | SUCH AS (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID OR SALT | AMERICAN HOME PRODUCTS CORPORATION | 2001-05-15 | — | — | US | claimed |
| EP-1077967-B1 | BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | WYETH CORP (US) | 2002-12-04 | — | — | EP | disclosed |
| US-6391897-B2 | (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID, FOR EXAMPLE; INHIBIT PROTEIN-TYROSINE PHOSPHATASES (PTPASES) | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-6369072-B2 | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-20010053785-A1 | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2001-12-20 | — | — | US | disclosed |
| US-20010041715-A1 | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PRODUCTS | 2001-11-15 | — | — | US | disclosed |
| US-6232322-B1 | SUCH AS (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID OR SALT | AMERICAN HOME PRODUCTS CORPORATION | 2001-05-15 | — | — | US | disclosed |
| EP-1077967-A2 | BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058518-A2 | BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053785-A1 | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, IAPP | PTPN1 1004/4885PTPRF 1176/4885PTPRA 1115/4885 |
| US-20010041715-A1 | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, IAPP | PTPN1 1004/4885PTPRF 1176/4885PTPRA 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.